Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr1.27
>-kr0.01(-0.47%)
At close: 4:00 PM EDT
kr1.27
>-kr0.01(-0.47%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume77.75K
Average Volume (3M)373.34K
Market Cap
kr432.83M
Enterprise Valuekr135.56
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)kr17.70M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and a substantial equity base (253.2M) give Intervacc durable financial optionality. This reduces refinancing risk, supports continued R&D and commercialization spending, and preserves negotiating power for partnerships or licensing over the next several quarters.
Commercialized VaccineHaving an on-market product (Strangvac) establishes product-market fit and a recurring revenue stream tied to sales and distribution agreements. A commercial vaccine and partner channels create a sustainable foundation for scale and future licensing or geographic rollouts.
Improving Cash Flow TrendFree cash flow improving by ~48% versus the prior period signals progress in narrowing the cash gap. If sustained, it indicates operational traction and better capital efficiency, improving runway and reducing the pace at which external financing is required.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flows (~-65.7M OCF, -67.2M FCF TTM) are structurally risky. Continued burn requires new capital or partner-funded programs, constraining strategic flexibility and risking dilution or interrupted commercialization if funding gaps emerge.
Negative Gross ProfitNegative gross profit indicates product sales are not covering direct costs at current volumes/pricing, a structural issue for sustainability. Deep operating losses (EBIT ~-415%) can erode equity over time and require either margin improvement or material volume increases to reverse.
Small, Declining Revenue BaseA modest revenue base (18.9M TTM) with a recent ~6% decline limits economies of scale and makes margin recovery difficult. Reliance on a single primary product and partner-led commercialization concentrates execution risk and slows the path to consistent profitability.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr432.83M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 16 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―